Piper Sandler Raises Verona Pharma (VRNA) PT to $160

Verona Pharma plc (NASDAQ: VRNA) saw Piper Sandler raise its price target on the stock to $160 from $76, maintaining an “Overweight” rating. The drug Ohtuvayre is expected to reach blockbuster status by 2027 due to its dual bronchodilation and anti-inflammatory effects for COPD treatment.

Ohtuvayre’s strong US launch for COPD showed 95% net sales growth in Q1 2025 compared to Q4 2024. Refills accounted for ~60% of dispenses, with new patient starts over 25% higher than the previous quarter. A newly granted patent for Ohtuvayre, valid until June 2044, was added to the FDA’s Orange Book.

TimesSquare Capital Management noted in their Q1 2025 investor letter that Verona Pharma exceeded estimates with the launch of Ensifentrine for COPD treatment. The company focuses on respiratory disease therapies and received FDA approval for their product, showcasing strong performance in the first two quarters.

While Verona Pharma (VRNA) shows investment potential, other AI stocks may offer greater upside with less risk. For those interested in undervalued AI stocks, a free report on the best short-term AI stock is available. Check out 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now for more investment opportunities.

Read more at Yahoo Finance: Piper Sandler Lifts PT on Verona Pharma (VRNA) Stock, Maintains Overweight